BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

Table 2

The genotype frequencies for BMP-4 polymorphisms between responders and nonresponders.

	Responders		Nonresponders		Adjusted OR^†, 95% CI	Adjusted 𝑃^†
	𝑁=364	%	𝑁=562	%
−5826G > A
GG	112	31%	184	32%	1
GA	171	47%	283	49%	0.99, 0.73–1.34	0.96
AA	81	22%	107	19%	1.24, 0.86–1.80	0.25
G	395	54%	651	57%	1
A	333	46%	497	43%	1.12, 0.92–1.33	0.3
6007C > T
TT	70	19%	179	31%	1
CT	167	46%	278	48%	1.34, 0.98–2.11	0.051
CC	127	35%	117	20%	2.78, 1.91–4.03	<0.001
T	307	42%	636	55%	1
C	421	58%	512	45%	1.72, 1.41–2.05	<0.001

†Adjusted with age, sex, smoke status, histology, stage, and chemotherapy agents.